NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00320359,Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00320359,,COMPLETED,Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer,NO,"Lung Cancer, Small Cell",DRUG: Intravenous topotecan/cisplatin|DRUG: Intravenous etoposide/cisplatin,"Median overall survival time of participants, Up to 1 year after randomization of the last patient","Number of participants with one year survival rate of the participants, Up to 1 year after randomization of the last patient|Median time of disease progression, up to 1 year after randomization of the last patient|Median time to event (progressive disease or death) of participants, Up to 1 year after randomization of the last patient|Median time to response to chemotherapy, Up to 1 year after randomization of the last patient|Median response duration, Up to 1 year after randomization of the last patient|Number of participants with objective response, Up to 1 year after randomization of the last patient|Mean lung cancer symptom score (LCSS), Up to 18 weeks|Mean eastern cooperative oncology group (ECOG) score, Up to 18 weeks|Number of participants with adverse events (AEs) and serious adverse events (SAEs), Up to 1 year after randomization of the last patient|Mean change from Baseline in hemoglobin value, Baseline and up to 18 weeks|Mean change from Baseline in leukocytes, neutrophils and platelets count, Baseline and up to 18 weeks|Mean change from Baseline in red blood cells (RBCs), Baseline and up to 18 weeks|Mean change from Baseline in Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase and Lactate dehydrogenase (LDH), Baseline and up to 18 weeks|Mean change from Baseline in Blood urea nitrogen (BUN), Potassium, Sodium and urea, Baseline and up to 18 weeks|Mean change from Baseline in Creatinine and Total bilirubin, Baseline and up to 18 weeks|Mean change from Baseline in Creatinine clearance|Mean change from Baseline in total protein, Baseline and up to 18 weeks|Number of participants with abnormal urinalysis results|Mean change from Baseline in weight, Baseline and up to 18 weeks|Mean change from Baseline in Body surface area, Baseline and up to 18 weeks",,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE3,700,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,104864-A/479,2002-08,2007-02,2007-02,2006-05-03,,2017-03-01,"GSK Investigational Site, Bludesch, A-6719, Austria|GSK Investigational Site, Klagenfurt, A-9020, Austria|GSK Investigational Site, Linz, A-4020, Austria|GSK Investigational Site, Vienna, A-1140, Austria|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, 79106, Germany|GSK Investigational Site, Karlsruhe, Baden-Wuerttemberg, 76137, Germany|GSK Investigational Site, Loewenstein, Baden-Wuerttemberg, 74245, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, 68167, Germany|GSK Investigational Site, Wangen, Baden-Wuerttemberg, 88239, Germany|GSK Investigational Site, Bayreuth, Bayern, 95445, Germany|GSK Investigational Site, Muenchen, Bayern, 80336, Germany|GSK Investigational Site, Nuernberg, Bayern, 90340, Germany|GSK Investigational Site, Passau, Bayern, 94032, Germany|GSK Investigational Site, Regensburg, Bayern, 93049, Germany|GSK Investigational Site, Rosenheim, Bayern, 83022, Germany|GSK Investigational Site, Cottbus, Brandenburg, 03048, Germany|GSK Investigational Site, Frankfurt/Oder, Brandenburg, 15236, Germany|GSK Investigational Site, Frankfurt, Hessen, 60431, Germany|GSK Investigational Site, Frankfurt, Hessen, 65929, Germany|GSK Investigational Site, Giessen, Hessen, 35392, Germany|GSK Investigational Site, Greifenstein, Hessen, 35753, Germany|GSK Investigational Site, Kassel, Hessen, 34125, Germany|GSK Investigational Site, Limburg, Hessen, 65549, Germany|GSK Investigational Site, Marburg, Hessen, 35043, Germany|GSK Investigational Site, Offenbach, Hessen, 63069, Germany|GSK Investigational Site, Wiesbaden, Hessen, 65199, Germany|GSK Investigational Site, Greifswald, Mecklenburg-Vorpommern, 17487, Germany|GSK Investigational Site, Neubrandenburg, Mecklenburg-Vorpommern, 17036, Germany|GSK Investigational Site, Rostock, Mecklenburg-Vorpommern, 18057, Germany|GSK Investigational Site, Rostock, Mecklenburg-Vorpommern, 18059, Germany|GSK Investigational Site, Stralsund, Mecklenburg-Vorpommern, 18437, Germany|GSK Investigational Site, Waren, Mecklenburg-Vorpommern, 17192, Germany|GSK Investigational Site, Goettingen, Niedersachsen, 37075, Germany|GSK Investigational Site, Leer, Niedersachsen, 26789, Germany|GSK Investigational Site, Stade, Niedersachsen, 21680, Germany|GSK Investigational Site, Bielefeld, Nordrhein-Westfalen, 33604, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, 44791, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, 53111, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, 53113, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, 53177, Germany|GSK Investigational Site, Coesfeld, Nordrhein-Westfalen, 48653, Germany|GSK Investigational Site, Dorsten, Nordrhein-Westfalen, 46282, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, 47166, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, 47228, Germany|GSK Investigational Site, Hamm, Nordrhein-Westfalen, 59071, Germany|GSK Investigational Site, Hemer, Nordrhein-Westfalen, 58675, Germany|GSK Investigational Site, Herne, Nordrhein-Westfalen, 44625, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, 50924, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, 50931, Germany|GSK Investigational Site, Krefeld, Nordrhein-Westfalen, 47798, Germany|GSK Investigational Site, Oberhausen, Nordrhein-Westfalen, 46145, Germany|GSK Investigational Site, Velbert, Nordrhein-Westfalen, 42551, Germany|GSK Investigational Site, Wuppertal, Nordrhein-Westfalen, 42283, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, 56073, Germany|GSK Investigational Site, Ludwigshafen, Rheinland-Pfalz, 67063, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, 55131, Germany|GSK Investigational Site, Trier, Rheinland-Pfalz, 54290, Germany|GSK Investigational Site, Halle/Saale, Sachsen-Anhalt, 06114, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, 39120, Germany|GSK Investigational Site, Chemnitz, Sachsen, 09113, Germany|GSK Investigational Site, Leipzig, Sachsen, 04207, Germany|GSK Investigational Site, Plauen, Sachsen, 08529, Germany|GSK Investigational Site, Borstel, Schleswig-Holstein, 23845, Germany|GSK Investigational Site, Flensburg, Schleswig-Holstein, 24939, Germany|GSK Investigational Site, Grosshansdorf, Schleswig-Holstein, 22927, Germany|GSK Investigational Site, Erfurt, Thueringen, 99089, Germany|GSK Investigational Site, Jena, Thueringen, 07747, Germany|GSK Investigational Site, Berlin, 10117, Germany|GSK Investigational Site, Berlin, 12200, Germany|GSK Investigational Site, Berlin, 12559, Germany|GSK Investigational Site, Berlin, 13125, Germany|GSK Investigational Site, Berlin, 13353, Germany|GSK Investigational Site, Berlin, 13585, Germany|GSK Investigational Site, Berlin, 14089, Germany|GSK Investigational Site, Berlin, 14109, Germany|GSK Investigational Site, Bremen, 28325, Germany|GSK Investigational Site, Hamburg, 20246, Germany|GSK Investigational Site, Hamburg, 21075, Germany|GSK Investigational Site, Hamburg, 22043, Germany",
